论文部分内容阅读
目的研究血管生成抑制剂SU6668对胃癌生长和转移的抑制作用。方法完整组织块SCID鼠胃壁原位种植,建立类似于临床的胃癌转移模型。将裸鼠48只随机分为4组,每组12只。移植后第7天开始,分别自腹腔注射生理盐水(对照组)、氟尿嘧啶(5-FU组)、SU6668制剂(SU6668组)、5-FU和SU6668制剂联合应用(5-FU加SU6668组),每日1次。共6周。种植后第8周末处死动物。原位肿瘤切除称重,计算抑瘤率、测定肿瘤微血管密度(MVD)和细胞凋亡指数(AI),并检查转移情况,计算转移抑制率。结果对照组、5-FU组、SU6668组和5-FU加SU6668组的抑瘤率分别为0、47．5%、64．1%和69．2%；MVD分别为13．4±5．4、11．6±5．1、6．6±3．1和4．8±2．9；AI分别为3．67±2．93、6．52±4．19、9．25±5．11和14．83±7．95；肝转移抑制率分别为0、25%、62．5%和74．9%；腹膜转移抑制率分别为0、19．9%、69．9%和90%。SU6668组和5-FU加SU6668组胃癌生长和转移受到明显抑制,以5-FU加SU6668联用组效果最明显。结论SU6668对胃癌生长和转移有明显抑制作用,与5-FU联用可起协同抑制作用。
Objective To study the inhibitory effect of SU6668, an angiogenesis inhibitor, on the growth and metastasis of gastric cancer. Methods The gastric tissue of SCID mice was implanted in situ and established a clinical model of gastric cancer metastasis. 48 nude mice were randomly divided into 4 groups, 12 in each group. From the 7th day after transplantation, the rats were treated with 5-FU and SU6668 by intraperitoneal injection of saline (control group), 5-fluorouracil group (SU6668 group), 5-FU and SU6668 group 1 day. A total of 6 weeks. Animals were sacrificed at the end of the 8th week after planting. In situ tumor resection and weighed, calculate the tumor inhibition rate, determination of tumor microvessel density (MVD) and apoptosis index (AI), and check the transfer, calculate the transfer inhibition rate. Results The tumor inhibition rates of control group, 5-FU group, SU6668 group and 5-FU plus SU6668 group were 0,47.5%, 64.1% and 69.2%, respectively; MVD was 13.4 ± 5 respectively. 4, 11.6 ± 5.1, 6.6 ± 3.1, and 4.8 ± 2.9; AI, respectively, 3.67 ± 2.93, 6.52 ± 4.19, 9.25 ± 5 .11 and 14.83 ± 7.95 respectively; the inhibition rate of hepatic metastasis was 0, 25%, 62.5% and 74.9% respectively; the inhibition rates of peritoneal metastasis were 0, 19.9% and 69.9% 90%. The growth and metastasis of gastric cancer in SU6668 group and 5-FU plus SU6668 group were significantly inhibited, and the combination of 5-FU plus SU6668 group was the most effective. Conclusion SU6668 can significantly inhibit the growth and metastasis of gastric cancer, and synergistic inhibitory effect with 5-FU can be obtained.